TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04287491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculus Go Virtual Reality System
Description: The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
Study: NCT05395806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health App
Description: The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
Study: NCT06088706

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular injection of ozone
Description: the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of ozone
Description: the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular injection of ozone
Description: the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
Study: NCT05040321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIB-626
Description: Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive either the placebo or 500mg MIB-626 twice daily orally.
Study: NCT06190639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200 mg once on day 1, every 21 days
Study: NCT05810623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical Solution
Description: Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
Study: NCT04541576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merit WRAPSODY Endovascular Stent Graft
Description: Target lesion treated with stent graft placement
Study: NCT05230810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer
Study: NCT05193864

Intervention type: DEVICE
Intervention: Device: JVPHome and ultrasound
Description: Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
Study: NCT01739478

Intervention type: OTHER
Group type: OTHER
Intervention: Packing of abscess cavity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External dressing
Description: Application of external dressing whilst abscess cavity heals

Intervention type: OTHER
Group type: OTHER
Intervention: External dressing
Description: Application of external dressing whilst abscess cavity heals
Study: NCT05268939

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 & Flu A/B test
Description: Swab Samples for Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 & Flu A/B test
Description: Swab Samples for Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 & RSV test
Description: Swab Samples for Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 & RSV test
Description: Swab Samples for Diagnostic test
Study: NCT06123104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)
Description: Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)
Description: Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
Study: NCT06637358

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended Scheduled Gradual Reduction (SGR)
Description: The extended SGR program will allow participants additional time to reduce smokeless tobacco use until they reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Scheduled Gradual Reduction (SGR)
Description: The extended SGR program will allow participants additional time to reduce smokeless tobacco use until they reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit Coach
Description: Weekly check-ins and support will be given to this group via the quit coach interactions. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
Study: NCT06161987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early comprehensive rehabilitation
Description: Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
Study: NCT04363112

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mini Kid II
Description: Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
Study: NCT05356494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural drainage
Description: (Group A will be treated with postural drainage)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure
Description: (Group B will be treated with positive expiratory pressure technique).
Study: NCT04324554

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI of the right knee
Description: An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
Study: NCT03747328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: nanoparticle albumin bound sirolimus
Study: NCT06466941

Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: Patients who underwent surgery and received an epidural or peripheral nerve block

Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: Patients who underwent surgery and received an epidural or peripheral nerve block

Intervention type: PROCEDURE
Intervention: no regional anesthesia
Description: Patients who underwent surgery and did not received an epidural or peripheral nerve block

Intervention type: PROCEDURE
Intervention: no regional anesthesia
Description: Patients who underwent surgery and did not received an epidural or peripheral nerve block

Intervention type: OTHER
Intervention: acute pain consultation
Description: Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation

Intervention type: OTHER
Intervention: no acute pain consultation
Description: Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
Study: NCT06635824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acasunlimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study: NCT05142865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg given orally, once daily in 21-day cycle
Study: NCT05328258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Embonate
Description: 11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug.
Study: NCT06581432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib
Study: NCT05940194

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVIVAC vaccine
Description: For prevention Covid-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC vaccine
Description: For prevention Covid-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC vaccine
Description: For prevention Covid-19
Study: NCT06446063

Intervention type: OTHER
Intervention: Test product
Description: Twice daily applications The product is applied to the entire face.

Intervention type: OTHER
Intervention: Control Product
Description: Twice daily applications The product is applied to the entire face.
Study: NCT06506032

Intervention type: DRUG
Intervention: Intravenous Vancomycin administration
Description: Vancomycin was administered to the patients at the discretion of the physician

Intervention type: OTHER
Intervention: Standard postoperative therapy
Description: The patients received standard postoperative therapy
Study: NCT05086757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRRP
Description: Receive TRRP services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants will receive an educational flyer with service referrals
Study: NCT06079736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGN-EDO51
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGN-EDO51
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGN-EDO51
Description: IV infusion
Study: NCT06171789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO1107
Description: Intravenous infusion of PRO1107
Study: NCT06055842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: over-denture
Description: implant retained overdenture prosthesis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: over-denture
Description: implant retained overdenture prosthesis.
Study: NCT04695600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: 100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: 100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
Study: NCT05223231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-019 Injection
Description: initial dose-MTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody injection
Description: provide medicine base on needs
Study: NCT06318806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
Study: NCT05498233

Intervention type: DRUG
Group type: OTHER
Intervention: Doxylamine + Pyridoxine
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Doxylamine + Pyridoxine
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study: NCT05151640

Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study: NCT04681833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo
Description: Low Repeat Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
Description: High Repeat Dose/High Repeat Multiple Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
Description: High Repeat Dose/High Repeat Multiple Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid diluent/Lyophilised Powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid diluent/Lyophilised Powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid diluent/Lyophilised Powder
Study: NCT04527380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study: NCT06481592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.
Study: NCT04949100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief
Description: * Duration: 60 minutes.~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Frequency: Each lead delivers a dual channel microcurrent of 10 and 40 Hz simultaneously.~* Amperage: Adjusted according to BMI: 100 μA for an underweight BMI less 20, 300μA for an overweight BMI greater than 30, and 200μA for normal BMI (20-30). Amperage may be adjusted to 20-300 μA according to comfort.~* Positioning: The patient remains seated for the first 10 minutes with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief
Description: * Duration: 60 minutes.~* Frequency: None~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Amperage: None~* Positioning: The patient remains seated for the first 10 minutes, again, with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment.
Study: NCT06345950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal Glutathione
Description: A maximum single dose of 500 mg glutathione (hard gel capsules)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Glutathione
Description: A maximum single dose of 500 mg glutathione (hard gel capsules)
Study: NCT05951868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuum of support on breastfeeding.
Description: A continuous support program for women from antenatal period till 6 months after delivery to initiate early breastfeeding, exclusively breastfeeding for 6 month and to continue breastfeeding till 2 years and beyond.
Study: NCT06345950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Micellar Glutathione (Lipomicel)
Description: A maximum single dose of 600 mg glutathione (soft gel capsules)
Study: NCT05882864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-Gingerol
Description: 6-gingerol gel will be applied locally to the participants suffering from oral lichen planus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 0.1% Oromucosal Paste
Description: Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
Study: NCT05489809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal extubation with suctioning
Description: General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal extubation with positive pressure
Description: General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
Study: NCT05693675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative methadone
Description: Participants will receive intraoperative methadone (0.2 mg/kg ideal body weight intravenously but not exceeding 20mg) followed by oral/IV methadone postoperatively according to the following scheme: A) Opioid naïve patients will receive 5mg twice daily dosage of methadone on postoperative days 1 and 2 followed by 5 mg daily on postoperative days 3, 4, and 5. B) Patients taking opioids preoperatively will continue to receive their regular opioids and additionally receive 5 mg twice a day of methadone on postoperative days 1 and 2, followed by 5 mg per day on days 3, 4 and 5.
Study: NCT05969548

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active 1200-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active 2400-pulse continuous Theta Burst Stimulation
Description: Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.